描述 |
Deslanoside (Desacetyllanatoside C) 是一种快速作用的强心苷,用于治疗充血性心力衰竭和因折返机制引起的室上性心律失常,并在治疗慢性心房颤动时控制心室率。Deslanoside 抑制Na-K-ATPase膜泵,导致细胞内钠和钙浓度增加。 |
---|---|
相关类别 |
|
体外研究 |
去乙酰甲苷(Desacetyllanatoside C)是兰豆苷C的代谢产物[4]。地塞米松增加前臂血流量和心脏指数,降低心率,同时骨骼肌交感神经活动显著降低,作为中枢介导交感神经系统活动的指标[1]。 |
存储 |
请将产品存放在分析证书中的建议条件下。
|
运输 |
室温 |
SMILES |
O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O[C@@](O[C@H](C)[C@H]3O[C@@](O[C@H](C)[C@H]4O[C@@](O[C@H](C)[C@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)([H])C[C@@H]5O)([H])C[C@@H]4O)([H])C[C@@H]3O)C1)C)([H])[C@]2([H])C[C@H]7O)(CC[C@@H]8C(CO9)=CC9=O)[C@]78C |
参考文献 |
[1]. Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70. [3]. Deslanoside.
|
密度 | 1.4±0.1 g/cm3 |
---|---|
熔点 | 220-235?C |
分子式 | C47H74O19 |
分子量 | 943.079 |
精确质量 | 942.482422 |
PSA | 282.21000 |
LogP | -1.40 |
折射率 | 1.620 |
储存条件 | 2-8°C |
去乙酰毛花苷毒性英文版
|
~%
去乙酰毛花苷
17598-65-1
|
文献:Helvetica Chimica Acta, , vol. 16, p. 1390,1407 Helvetica Chimica Acta, , vol. 17, p. 592,613 |
~%
去乙酰毛花苷
17598-65-1
|
文献:Advanced Synthesis and Catalysis, , vol. 355, # 13 p. 2518 – 2524 |
~91%
去乙酰毛花苷
17598-65-1
|
文献:Muramatsu, Wataru; Yoshimatsu, Hirofumi Advanced Synthesis and Catalysis, 2013 , vol. 355, # 13 p. 2518 – 2524 |
去乙酰毛花苷上游产品? 3 | |
---|---|
|
|
去乙酰毛花苷下游产品? 1 | |
|
Effects of acute administration of ethanol on experimental arrhythmia. Chin. J. Physiol. 55(5) , 307-13, (2012)
Many studies have shown that the relationship between alcohol consumption and most cardiovascular diseases is U-shaped, with nondrinkers and heavier drinkers having higher risks than moderate drinkers…
|
|
Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am. J. Physiol. 268(2 Pt 2) , R310-16, (1995)
We investigated alterations in autonomic control of heart rate in conscious dogs with left ventricular (LV) dysfunction in the presence and absence of heart failure (HF) due to rapid pacing. In dogs w…
|
|
Two-stage cultivation of Digitalis lanata cells: semicontinuous production of deacetyllanatoside C in 20-litre airlift bioreactors. J. Biotechnol. 16(1-2) , 123-35, (1990)
A two-stage cultivation method was employed to develop a semicontinuous biotransformation process for the production of deacetyllanatoside C, a cardenolide of the important digoxin series. Digitoxin w…
|
|
Card-20(22)-enolide, 3-((O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3β,5β,12β)- |
Deacetyllanatoside C |
Desacetyllanatoside C |
Deslanatoside C |
Deslanoside |
Deacetyllanatoside C,Desacetyllanatoside C |
Cedilanide |
(3β,5β,12β)-3-{[β-D-Glucopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide |
deacetyl-lanatoside |
4-18-00-02455 (Beilstein Handbook Reference) |
Desacetyldigilanide C |
Descetyldigilanide C |
DESLANOSIDUM |
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone |
Desaci |
Desace |
MFCD00135818 |
deacetyl-lanatoside C |
Card-20(22)-enolide, 3-[[O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-d ihydroxy-, (3β,5β,12β)- |
Deslanatoside |
Purpurea Glycoside C |
Desacetyllanatosid C |
card-20(22)-enolide, 3-[[O-β-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)- |
glucodigoxin |
Deslanosidum C |
(3β,5β,12β)-3-{[β-D-Glucopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydro
 xycard-20(22)-enolide |
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-méthyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxyméthyl)tétrahydro-2H-pyran-2-yl]oxy}tétrahydro-2H-pyran-2-yl]oxy}-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-10,13-diméthylhexadécahydro-1H-cyclopenta[a]phénanthrén-17-yl]-2(5H)-furanone |
cedilanidd |
sediranido |
EINECS 241-568-1 |
de-O-acetyl-lanatoside C |
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-Dihydroxy-3-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanon |